Gemtuzumab_Ozogamicin: profile and news

Acceleron Pharma Appoints Matthew L. Sherman, MD as Chief Medical ... 16 May 2006
...projects for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg(R) (gemtuzumab ozogamicin for injection) by the ... - Genetic Engineering News, ssi/2005_09_07/Gemtuzumab_Ozogamicin.txt" -->

Mylotarg® Followed by Allogeneic Stem Cell Transplantation ... Sep 28, 2005
Researchers involved in the Mylotarg Study Group have published the final report of the effectiveness of Mylotarg (gemtuzumab ozogamicin) for the treatment of ... - Cancer Consultants (press release),

Mylotarg® Effective for Relapsed Acute Myeloid Leukemia Oct 3, 2005
Among patients with a first recurrence of acute myeloid leukemia, 26% achieved remission after treatment with Mylotarg® (gemtuzumab ozogamicin), according to ... - Cancer Consultants (press release),

Antibody-Targeted Chemotherapy Shows Promise for Pediatric AML 08 Sep 2005
NEW YORK SEP 07, 2005 (Reuters Health) - Chemotherapy targeted by gemtuzumab ozogamicin provides remissions for some children with advanced CD33+ acute myeloid ... - Cancerpage.com,

Effects of Mylotarg® in Pediatric Patients with Relapsed or ... Aug 30, 2005
...partial and complete remission rate in children with relapsed or refractory acute myeloid leukemia (AML) with single agent Mylotarg (gemtuzumab ozogamicin). ... - Cancer Consultants (press release),

International Approvals: Concerta, Mylotarg, Remodulin Aug 15, 2005
...disorder in adolescents aged 13 to 18 years; Japan's Ministry of Health, Labor, and Welfare has approved gemtuzumab ozogamicin intravenous injection for the ... - Medscape (subscription)

Mylotarg® Effective in Pediatric Patients with Relapsed or ... Aug 18, 2005
According to a recent article published in the journal Blood, the targeted agent Mylotarg® (gemtuzumab ozogamicin) provides anti-cancer responses in children ... - Cancer Consultants (press release),

Immunodiagnostics Shape Immunotherapeutics for Improved Cancer ... Aug 24, 2005
Recent US Food and Drug Administration (FDA) approval of rituximab, gemtuzumab ozogamicin, alemtuzumab, and ibritumomab tiuxetan for cancer radioimmunotherapy ... - Medscape (subscription)

J&J Zarnestra Efficacy Rate Likely To Be Focus Of Oncology Cmte. ... May 4, 2005
The only other AML therapy indicated specifically for the elderly population, Wyeth’s Mylotarg (gemtuzumab ozogamicin), was associated with a 16% complete ... - FDA Advisory Committee

Genta Incorporated Announces Fourth Quarter and Year End 2004 ... Feb 17, 2005
Acute myeloid leukemia (AML): At the December 2004 ASH meeting, results from a Phase 2 trial of Genasense plus Mylotarg(R) (gemtuzumab ozogamicin) showed that ... - Yahoo News (press release)

Other information

Indication
For treatment of acute myeloid leukemia

Pharmacology
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.

Mechanism Of Action
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.

Drug Category
Antineoplastic Agents

Brand Names/Synonyms
Mylotarg; anti-CD33; Mylotarg (Wyeth)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized chimeric anti-CD33 antibody

Chemical Formula
Not Available

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
BIOD00077

CAS Registry Number
220578-59-6